Alzprotect focuses its research on tauopathies where neuronal degeneration is the consequence of the abnormal aggregation of hyperphosporylated Tau proteins combined with inflammation. This mechanism is found in Progressive Supranuclear Palsy (PSP), an orphan disease, and in Alzheimer’s disease (AD).
Our therapeutic strategy is unique in the market and aims at stopping the neurodegeneration process and, where possible, restoring cognitive functions.
AZP2006 is different from the other molecules developed so far.
Indeed, its mechanism of action addresses all the causes of neurodegeneration, including amyloid peptide toxicity, Tau phosphorylation, oxidative stress and neuroinflammation.
This innovative mechanism of action involves the regulation of complex intracellular processes including inflammatory pathways and neuronal survival. The mode of action is based on the levels of a neurotrophic factor: progranulin.
This novel approach, currently the only one of its kind in the world, may not only stop the disease progression process for all markers, but also potentially restore the growth of neuronal connections.
The first molecule issued from this research, AZP2006, offers a very effective mechanism of action against neurodegeneration and could lead to new therapeutic solutions for the treatment of Progressive Supranuclear Palsy (PSP), Alzheimer’s disease (AD) and Parkinson’s disease.